Parenting and CAH - 21-hydroxylase Deficiency
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 21, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the genetic condition known as congenital adrenal hyperplasia (CAH), specifically the 21-hydroxylase deficiency (21OHD) type, affects women, particularly in terms of their sexuality, fertility, and pregnancy outcomes. CAH is caused by a problem with a gene that helps the body produce certain hormones. The trial aims to gather more information about how this condition impacts women and their experiences, as there is currently limited data available.
To be eligible for this trial, participants must be women aged 18 or older who have been genetically confirmed to have 21-hydroxylase deficiency. They should also be able to understand and agree to participate in the research. Unfortunately, women who do not speak French or who are under legal protection cannot join the study. Those who participate can expect to share their experiences and possibly receive information that could help improve care for others with this condition. Overall, this trial hopes to shed light on important aspects of living with CAH and to improve the support and treatment options available for affected women.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 or over
- • Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically
- • Patients who have been informed and do not object to participating in the research
- Exclusion Criteria:
- • Patients who do not speak French
- • Patients who are not affiliated to a social security scheme or who are not entitled to it
- • Patients under legal protection, or under guardianship or trusteeship.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported